SNDL Inc
F:VY4

Watchlist Manager
SNDL Inc Logo
SNDL Inc
F:VY4
Watchlist
Price: 1.85 EUR -0.22% Market Closed
Market Cap: 488.9m EUR
Have any thoughts about
SNDL Inc?
Write Note

Relative Value

The Relative Value of one VY4 stock under the Base Case scenario is 2.14 EUR. Compared to the current market price of 1.85 EUR, SNDL Inc is Undervalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VY4 Relative Value
Base Case
2.14 EUR
Undervaluation 13%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
66
vs Industry
76
Median 3Y
0.9
Median 5Y
1.4
Industry
2.6
Forward
0.8
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-3.1
Industry
23
Forward
-16.2
vs History
6
vs Industry
21
Median 3Y
-10.5
Median 5Y
-9.8
Industry
17.8
vs History
1
vs Industry
Median 3Y
-8.1
Median 5Y
-7.2
Industry
25.4
vs History
49
vs Industry
72
Median 3Y
0.6
Median 5Y
0.7
Industry
2.2
vs History
69
vs Industry
79
Median 3Y
0.8
Median 5Y
1.7
Industry
2.8
Forward
0.7
vs History
69
vs Industry
61
Median 3Y
3.3
Median 5Y
8.8
Industry
5.4
vs History
15
vs Industry
4
Median 3Y
-16.2
Median 5Y
-11.3
Industry
13.7
Forward
24.8
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-11.1
Industry
17.2
Forward
-56.3
vs History
6
vs Industry
23
Median 3Y
-8.7
Median 5Y
-6.4
Industry
16.5
vs History
6
vs Industry
18
Median 3Y
-8.2
Median 5Y
-5.8
Industry
19.3
vs History
42
vs Industry
73
Median 3Y
0.5
Median 5Y
0.5
Industry
2

Multiples Across Competitors

VY4 Competitors Multiples
SNDL Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
SNDL Inc
F:VY4
488.9m EUR 0.8 -6.4 47.4 -13.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.5B USD 18.5 90.4 48.6 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
364.1B USD 4.2 24.8 12 15.6
US
Merck & Co Inc
NYSE:MRK
248.4B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.5B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.9
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.5 169.4 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
CA
SNDL Inc
F:VY4
Average P/E: 33.3
Negative Multiple: -6.4
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.8
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A
EV/EBIT Multiple
EBIT Growth
CA
SNDL Inc
F:VY4
Average EV/EBIT: 2 075.6
Negative Multiple: -13.4
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
212%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
DK
Novo Nordisk A/S
CSE:NOVO B
27.8
85%
US
Johnson & Johnson
NYSE:JNJ
15.6
29%
US
Merck & Co Inc
NYSE:MRK
12.4
695%
CH
Roche Holding AG
SIX:ROG
12.1
27%
CH
Novartis AG
SIX:NOVN
14.9
54%
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
IE
E
Endo International PLC
LSE:0Y5F
587.7
N/A

See Also

Discover More
Back to Top